Evidence map›Paper›PMID 33504919›Full record

ArticleThe Journal of antibiotics2021

Synthesis, antibacterial action, and ribosome inhibition of deoxyspectinomycins.

Suresh Dharuman, Laura A Wilt, Jiuyu Liu, Stephanie M Reeve, Carl W Thompson, John M Elmore, Dimitri Shcherbakov, Robin B Lee, Erik C Böttger, Richard E Lee

Open access · hybridAbstract read
In one paragraph

Article in The Journal of antibiotics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Development of 2nd generation aminomethyl spectinomycins that overcome native efflux inProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Suresh DharumanDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-5491-6677
Laura A WiltDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jiuyu LiuDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Stephanie M ReeveDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0003-2064-405X
Carl W ThompsonDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA.
John M ElmoreDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Dimitri ShcherbakovInstitut für Medizinische Mikrobiologie, Universität Zürich, Zürich, Switzerland.
Robin B LeeDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Erik C BöttgerInstitut für Medizinische Mikrobiologie, Universität Zürich, Zürich, Switzerland.
Richard E LeeDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA. Richard.Lee@stjude.org.ORCID http://orcid.org/0000-0002-2397-0443
St. Jude Children's Research Hospital · USUniversity of Zurich · CH

Funding

Development of Novel Proteins Synthesis Inhibitors for MDR TuberculosisR01AI090810 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LEE, RICHARD E. · 2010 to 2022
$8.9M
Combating resistant superbugs by understanding the molecular determinants of target site penetration and bindingR01AI136803 · NIAID · UNIVERSITY OF FLORIDA · PI BULITTA, JURGEN BERND · 2018 to 2022
$5.7M
Spectinomycin analogs for NTM infectionsR01AI157312 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LEE, RICHARD E. · 2020 to 2024
$4.1M
Training in the Design and Development of Infectious Disease TherapeuticsT32AI106700 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Richard E. Lee · 2015 to 2026
$2.1M
NIAID NIH HHS R01 AI090810NIAID NIH HHS R01AI090810NIAID NIH HHS R01 AI136803NIAID NIH HHS R01AI136803NIAID NIH HHS R01 AI157312NIAID NIH HHS T32 AI106700NIAID NIH HHS T32AI106700
6 · The paper itself

Abstract

Spectinomycin, an aminocyclitol antibiotic, is subject to inactivation by aminoglycoside modifying enzymes (AMEs) through adenylylation or phosphorylation of the 6-hydroxy group position. In this study, the effects of deoxygenation of the 2- and 6-hydroxy group positions on the spectinomycin actinamine ring are probed to evaluate their relationship to ribosomal binding and the antimicrobial activities of spectinomycin, semisynthetic aminomethyl spectinomycins (amSPCs), and spectinamides. To generate these analogs, an improved synthesis of 6-deoxyspectinomycin was developed using the Barton deoxygenation reaction. 6-Dehydrospectinamide was also synthesized from spectinamide 4 to evaluate the H-bond acceptor character on the C-6 position. All the synthesized analogs were tested for antibacterial activity against a panel of Gram (+) and Gram (-) pathogens, plus Mycobacterium tuberculosis. The molecular contribution of the 2- and 6-hydroxy group and the aryl functionalities of all analogs were examined by measuring inhibition of ribosomal translation and molecular dynamics experiments with MM/GBSA analysis. The results of this work indicate that the 6-hydroxy group, which is the primary target of AMEs, is a required motif for antimicrobial activity in current analogs. Removal of the 6-hydroxy group could be partially rescued by offsetting ribosomal binding contributions made by the aryl side chains found in the spectinamide and amSPCs. This study builds on the knowledge of the structure-activity relationships of spectinomycin analogs and is being used to aid the design of next-generation spectinomycins.

Indexed as

Anti-Bacterial AgentsBacterial ProteinsMicrobial Sensitivity TestsMolecular Dynamics SimulationMycobacterium tuberculosisRibosomesSpectinomycinStructure-Activity RelationshipAnti-Bacterial AgentsBacterial ProteinsSpectinomycin

Identifiers

PMID33504919
PMCPMC8154590
OpenAlexW3121616717

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.